Thank you for your deep dive. Very interesting, I will hold an eye on this company. This reminds me on Immunitybio, only in oncology, but also with several platforms (bispecific antibodies, Car-NK and adenovirus platform). But in contrast to ABCL IBRX does have a PDUFA date for the first drug Anktiva this month. I did a deep dive in their platforms and summarised it here: https://optionicity.com/biotech/ibrx/platform.shtml . Feel free to use the data also from the many clinical trials.
muchas gracias tengo abcellera hace 27 meses usted aporta mucho valor de nuevo gracias saludos
Thank you for your deep dive. Very interesting, I will hold an eye on this company. This reminds me on Immunitybio, only in oncology, but also with several platforms (bispecific antibodies, Car-NK and adenovirus platform). But in contrast to ABCL IBRX does have a PDUFA date for the first drug Anktiva this month. I did a deep dive in their platforms and summarised it here: https://optionicity.com/biotech/ibrx/platform.shtml . Feel free to use the data also from the many clinical trials.
Happy to have inspired you 🙏
Looking forward to reading accurately and discuss it with you!
The links to your ‘Investmentideas.io’ website aren’t working. Any idea why? Thanks :)